Sage postpartum depression drug gets priority review at FDA, teeing up 2018 approval

Sage's brexanolone aced a small phase 2, but its superiority over placebo was less pronounced in the pivotal trials. (FDA)

The FDA has awarded priority review designation to Sage Therapeutics’ postpartum depression (PPD) drug brexanolone. Securing the status positions Sage to receive a decision from the FDA by the end of the year.

Before the December 19 PDUFA date, the FDA will hold an advisory committee meeting to talk about the submission. If that goes well, Sage could bring its first drug to market around the turn of the year and begin racking up the first sales of what some analysts think will be at least a $500-million-a-year product. 

The big question is what the FDA and its advisory committee will make of Sage’s data. Two phase 3 trials linked the intravenous formulation of allopregnanolone to statistically significant improvements on a depression scale, resulting in the studies hitting their primary endpoints. But the details of the data left scope for discussion about the value of the drug, particularly to certain groups of patients.


Webinar: Meet the Challenge of Complex Protein Expression

As market demand continues to rise for more potent and effective therapeutics, biologic pipelines are evolving from standard antibody formats to next-generation biologics (NGBs). In this webinar we will discuss and demonstrate application through case studies, two significant enhancements to Lonza’s GS Xceed® expression system to help address the challenges of NGBs.

Brexanolone aced a small phase 2 but its superiority over placebo was less pronounced in the pivotal trials, which recruited 226 patients between them. The divergence was smallest in the phase 3 trial that enrolled patients with moderate, not severe, forms of PPD. In these patients, brexanolone was no more effective than placebo after 30 days.

With Sage’s trial primarily looking at the efficacy of brexanolone after 60 hours, the convergence of depression scores in the treatment and placebo arms after 30 days is a blemish rather than a critical blow. But it is the sort of data point that could come into play as Sage seeks a broad label for brexanolone and then tries to persuade providers and payers to use and cover the drug.

The importance of standout efficacy for Sage commercially is amplified by the burden its drug puts on patients and providers. The version of brexanolone now under review at FDA is administered via a 60-hour infusion. Sage is working on an oral version, but in the near-term, taking brexanolone will be a major commitment. 

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”